Accession Number: | 0001209191-21-039233 |
Date: | 2021-06-08 |
Issuer: | AEGLEA BIOTHERAPEUTICS, INC. (AGLE) |
Original Submission Date: |
SHANAFELT ARMEN
C/O LILLY VENTURES
115 W WASHINGTON STREET, SUITE 1680
SOUTH INDIANAPOLIS, IN 46204
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
DIRECTOR STOCK OPTION (RIGHT TO BUY) | 6.8 | 2021-06-08 | deemed execution date | A | 40,000 (a) | 2031-06-07 | common stock 40,000 | $6.80 | 40,000 | direct |
ID | footnote |
---|---|
f1 | the stock option vests and becomes exercisable in 12 equal monthly installments beginning on july 8, 2021, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the reporting person on each vesting date. |